PDF(Pubmed)
Abstract：
BACKGROUND: Several trials evaluated the role of ovarian function suppression for the adjuvant treatment of premenopausal patients with hormone receptor-positive early breast cancer. Based on the results of the SOFT and TEXT trials, international guidelines recommend the addition of ovarian function suppression to standard adjuvant endocrine therapy for patients at higher risk of relapse.
METHODS: The ERA project (Evaluation of Risk factors in the Adjuvant treatment of breast cancer in premenopausal patients) was devised with the objective of obtaining a consensus on the identification of risk factors and the use of ovarian function suppression in the adjuvant treatment of these women. To this aim, a panel of 31 Italian oncologists with expertise in breast cancer participated in a Delphi consensus study in June 2017.
RESULTS: A total of 29 statements related to prognostic factors, therapeutic strategies and ovarian function suppression were defined and voted to gain final consensus. For each topic we report data supporting the acquired consensus and the relevant issues discussed.
CONCLUSIONS: The SOFT and TEXT trials have changed the standard adjuvant treatment of premenopausal patients with hormone receptor-positive early breast cancer, but the available treatment options require a careful risk assessment and toxicities evaluation to ensure the greatest clinical benefit for each patient.
METHODS: The ERA project (Evaluation of Risk factors in the Adjuvant treatment of breast cancer in premenopausal patients) was devised with the objective of obtaining a consensus on the identification of risk factors and the use of ovarian function suppression in the adjuvant treatment of these women. To this aim, a panel of 31 Italian oncologists with expertise in breast cancer participated in a Delphi consensus study in June 2017.
RESULTS: A total of 29 statements related to prognostic factors, therapeutic strategies and ovarian function suppression were defined and voted to gain final consensus. For each topic we report data supporting the acquired consensus and the relevant issues discussed.
CONCLUSIONS: The SOFT and TEXT trials have changed the standard adjuvant treatment of premenopausal patients with hormone receptor-positive early breast cancer, but the available treatment options require a careful risk assessment and toxicities evaluation to ensure the greatest clinical benefit for each patient.
摘要：
背景：一些试验评估了卵巢功能抑制在绝经前激素受体阳性早期乳腺癌患者的辅助治疗中的作用。根据SOFT和TEXT试验的结果，对于复发风险较高的患者,国际指南建议在标准辅助内分泌治疗中增加卵巢功能抑制.
方法：设计了ERA项目（绝经前乳腺癌患者辅助治疗中的危险因素评估），目的是在识别危险因素和在这些妇女的辅助治疗中使用卵巢功能抑制方面达成共识。为了这个目标,一个由31名具有乳腺癌专业知识的意大利肿瘤学家组成的小组于2017年6月参加了一项Delphi共识研究.
结果：共有29种与预后因素有关的陈述，定义了治疗策略和卵巢功能抑制,并投票达成最终共识.对于每个主题，我们报告数据支持获得的共识和讨论的相关问题。
结论：SOFT和TEXT试验改变了绝经前激素受体阳性早期乳腺癌患者的标准辅助治疗，但现有的治疗方案需要进行仔细的风险评估和毒性评估,以确保每位患者获得最大的临床获益.
方法：设计了ERA项目（绝经前乳腺癌患者辅助治疗中的危险因素评估），目的是在识别危险因素和在这些妇女的辅助治疗中使用卵巢功能抑制方面达成共识。为了这个目标,一个由31名具有乳腺癌专业知识的意大利肿瘤学家组成的小组于2017年6月参加了一项Delphi共识研究.
结果：共有29种与预后因素有关的陈述，定义了治疗策略和卵巢功能抑制,并投票达成最终共识.对于每个主题，我们报告数据支持获得的共识和讨论的相关问题。
结论：SOFT和TEXT试验改变了绝经前激素受体阳性早期乳腺癌患者的标准辅助治疗，但现有的治疗方案需要进行仔细的风险评估和毒性评估,以确保每位患者获得最大的临床获益.
